Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by SciSparc Ltd

< Previous 1 2 3 Next >
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Adopts Limited Duration Shareholder Rights Plan
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Granted European Patent for its Core Technology
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Announces 1-for-26 Reverse Share Split
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.